Stockscreener 앱 받기
6.28
7.17%
0.42
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
Fmr LLC Purchases 7,839 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 27,597 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Charles Schwab Investment Management Inc. Sells 1,649 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Enanta Pharmaceuticals' SWOT analysis: RSV pipeline progress buoys stock outlook - Investing.com
(ENTA) Technical Data - Stock Traders Daily
Enanta stock touches 52-week low at $6.36 amid market challenges - Investing.com Canada
FY2025 Earnings Estimate for ENTA Issued By Leerink Partnrs - Defense World
Leerink Partnrs Has Positive Outlook of ENTA FY2025 Earnings - MarketBeat
Enanta Pharmaceuticals CFO Paul Mellett sells shares worth $20,883 By Investing.com - Investing.com Canada
Enanta Pharmaceuticals' chief scientific officer sells $20,883 in stock By Investing.com - Investing.com Canada
Enanta Pharmaceuticals CFO Paul Mellett sells shares worth $20,883 - Investing.com
Enanta Pharmaceuticals' chief scientific officer sells $20,883 in stock - Investing.com
Point72 Asset Management L.P. Buys New Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat
Enanta Pharmaceuticals chief scientific officer sells shares worth $20,883 By Investing.com - Investing.com Nigeria
Enanta Pharmaceuticals' chief product strategy officer sells $18,400 in stock By Investing.com - Investing.com Canada
Enanta Pharmaceuticals CEO sells $41,444 in stock By Investing.com - Investing.com Nigeria
Enanta Pharmaceuticals CFO sells shares worth $20,883 - Investing.com
Enanta Pharmaceuticals CEO sells $41,444 in stock - Investing.com
Enanta Pharmaceuticals chief business officer sells $18,400 in stock By Investing.com - Investing.com Nigeria
Enanta Pharmaceuticals CFO sells shares worth $20,883 By Investing.com - Investing.com Nigeria
Enanta Pharmaceuticals chief business officer sells $18,400 in stock - Investing.com
Enanta Pharmaceuticals' chief product strategy officer sells $18,400 in stock - Investing.com
Enanta’s zelicapavir shows promise in paediatric respiratory syncytial virus trial - Yahoo Finance
Enanta logs phase II RSV win with zelicapavir - BioWorld Online
Enanta Pharmaceuticals Sees Positive Topline Results for RSV Drug Trials - MarketWatch
LogoEnanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) - Business Wire
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV) - BioSpace
Enanta's RSV Drug Zelicapavir Shows Strong Antiviral Effects in Landmark Pediatric Trial - StockTitan
Enanta Pharma to Unveil Breakthrough RSV Pediatric Trial ResultsKey Phase 2 Data Coming - StockTitan
Enanta stock touches 52-week low at $7.99 amid market challenges - Investing.com Nigeria
Erste Asset Management GmbH Purchases New Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat
Enanta Pharmaceuticals (FRA:9EP) 3-Year FCF Growth Rate : -9.20% (As of Sep. 2024) - GuruFocus.com
Caligan Partners LP Cuts Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - MarketBeat
Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $19.50 - MarketBeat
Enanta Pharmaceuticals Initiates Phase 1 Study of MRSA Infection Candidate EDP-788 - Marketscreener.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Receives Market Outperform Rating from JMP Securities - Defense World
Analysts Have Been Trimming Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target After Its Latest Report - Simply Wall St
Enanta Pharmaceuticals’ Reduced Reporting: Potential Impact on Investor Appeal and Stock Volatility - Yahoo Finance
Enanta Pharmaceuticals' SWOT analysis: RSV pipeline and cash position fuel stock outlook - Investing.com
ENTA (Enanta Pharmaceuticals) Accounts Receivable : $6.65 Mil (As of Sep. 2024) - GuruFocus.com
Robert W. Baird Has Lowered Expectations for Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price - Defense World
Enanta Pharmaceuticals Inc. (ENTA) reports earnings - Quartz
Benign Growth For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Underpins Stock's 27% Plummet - Simply Wall St
Enanta Pharmaceuticals (STU:9EP) Cash Flow from Operations : €-83.19 Mil (TTM As of Jun. 2024) - GuruFocus.com
Enanta stock touches 52-week low at $8.45 amid market challenges - Investing.com Canada
4 Analysts Assess Enanta Pharma: What You Need To Know - Benzinga
Leerink raises Enanta price target to $12 from $10, keeps rating - Investing.com UK
2.88%
2.65%
자본화:
|
볼륨(24시간):